FDA approves Rituxan as first targeted B-cell therapy for treatment of rheumatoid arthritis
Genentech, Inc. and Biogen Idec, Inc. announced today that the U.S. food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
Rituxan, discovered by Biogen Idec, is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells without targeting stem cells or existing plasma cells. In patients with RA, Rituxan is given as two 1000 mg IV infusions separated by two weeks, in combination with MTX. It is recommended to administer the steroid methylprednisolone 100 mg IV 30 minutes prior to each infusion. In addition to RA, Rituxan is being studied in other autoimmune diseases with significant unmet medical needs, including systemic lupus erythematosus, lupus nephritis, multiple sclerosis and ANCA-associated vasculitis.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Going back to nature - A look at processing systems for white biotech applications

Evonik invests US$220 million in partnership with the U.S. Government to build new lipid production facility for mRNA-based therapies in the U.S. - Important contribution to the development of new mRNA therapies beyond COVID-19 vaccines

Could the blood of COVID-19 patients be used to predict disease progression? - Study discovers differences in the blood samples of severe and mild cases

Achilles’ heel of dangerous hospital pathogen discovered - Structural analysis revealed weak spots
PANalytical becomes distributor for OBLF product line
Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells - New approach could dramatically improve the success rate of immune-cell therapies

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

Powering Nitrogenases: New ways for sustainable fertiliser production - New targets for improving biocatalysts
Immune cells can switch from ‘gang members’ to ‘police officers’
Bucking the trend - Bio Nano Consulting adds to team on back of contract wins
